China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) announced receiving clinical trial approval for its investigational adjuvanted quadrivalent influenza vaccine LZSN2401 in China. This marks a significant step forward in the development of more effective influenza prevention solutions.
Vaccine Innovation
LZSN2401 is positioned as the world’s first adjuvanted quadrivalent influenza vaccine to enter clinical trials. It is designed for influenza prevention in individuals aged 18 and above, with enhanced benefits for the elderly and immunocompromised populations. The vaccine utilizes an insect cell baculovirus expression system, eliminating the need for virus culture and offering improved safety profiles.
Enhanced Immunogenicity
The inclusion of innovative adjuvants in LZSN2401 enables the simultaneous activation of Th1/Th2 cellular immunity and humoral immunity. This advancement significantly improves the vaccine’s immunogenicity, providing stronger protection for high-risk groups such as the elderly and those with underlying diseases.-Fineline Info & Tech
Leave a Reply